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Abstract
Purpose This study aimed to clarify the long-term efﬁ-
cacy of the lamivudine treatment in Japanese patients with
chronic hepatitis B either with or without lamivudine
resistance or with or without adefovir add-on treatment.
Methods We followed 110 patients who received lamivu-
dine for more than 12 months, including 67 hepatitis B e
antigen (HBeAg)-positive and 43 HBeAg-negative patients.
Results The median follow-up after the onset of lamivu-
dine was 48 (range = 12–86) months. In all the patients
with or without lamivudine resistance, the level of alanine
aminotransferase (ALT) normalization decreased from
70.0% at 1 year to 36.4% at 5 years and the loss of serum
HBV DNA level decreased from 72.7% at 1 year to 31.8%
at 5 years. Sixty patients (54.6%) developed a lamivudine-
resistant mutation, and this occurrence was more frequently
observed in those who were HBeAg-positive (P\0.01),
those with a low level of ALT (P\0.05), and those with a
high level of serum HBV DNA (P\0.01). Thirty-six of 60
patients received adefovir in addition to lamivudine to treat
breakthrough hepatitis. A Cox proportional hazards model
analysis revealed the level of baseline HBV DNA to be the
best predictive factor for the virus recrudescence (risk
ratio = 0.466, 95% conﬁdence interval [CI]: 0.246–0.842,
P = 0.011) and the breakthrough hepatitis (risk ratio =
0.444, 95% CI: 0.218–0.879, P = 0.019). We carefully
monitored the efﬁcacy of this treatment both in patients
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DOI 10.1007/s12072-008-9081-2who received adefovir and in those who did not since the
beginning of the lamivudine treatment. The normalization
level of ALT was 61.4% at 5 years and the loss of serum
HBV DNA was 61.4% at 5 years since lamivudine was
started. A histologic improvement was observed in patients
with ALT levels less than two times the upper limit of
normal at the time of a second liver biopsy.
Conclusions Although the efﬁcacy of lamivudine is lim-
ited because of breakthrough hepatitis, adefovir was used
as a salvage treatment of patients with lamivudine-resistant
chronic hepatitis B. In addition, lamivudine was used for
the treatment of Japanese patients with chronic hepatitis B
with or without lamivudine resistance, and was found to be
useful regarding the long-term virologic and biochemical
responses.
Keywords Chronic hepatitis B  Lamivudine 
Adefovir
Introduction
The number of patients chronically infected with hepatitis
B virus (HBV) is reported to be more than 350 million
worldwide [1, 2]. These patients are at an increased risk to
develop cirrhosis, hepatic decompensation, and hepatocel-
lular carcinoma [3, 4]. The aims of treatment of chronic
hepatitis B are to achieve a sustained suppression in HBV
replication and remission in liver disease. The endpoints
used to assess the treatment response include the normal-
ization of the alanine aminotransferase (ALT) level, the
loss of serum HBV DNA, the loss of hepatitis B e antigen
(HBeAg) with or without the detection of antibody to
HBeAg (HBeAb), and an improvement in the liver
histology.
Interferon, which has been shown to have an antipro-
liferative effect on the virus, has been used for the
treatment of chronic hepatitis B; however, its efﬁcacy has
been limited to only a small percentage of preselected
patients [5, 6]. Lamivudine is the ﬁrst nucleoside analog to
be approved for the treatment of the patients with chronic
hepatitis B. Although the short-term efﬁcacy of lamivudine
therapy has been well documented, the occurrence of
lamivudine-resistant mutations has also been reported to
increase with extended use [7–9]. Adefovir dipivoxil is a
nucleotide analogue of adenosine monophosphate and has
been shown to be effective in suppressing not only wild-
type HBV but also lamivudine-resistant HBV [10, 11].
Lamivudine has been used in Japan since November
2000 for the treatment of patients with chronic hepatitis B.
Since December 2004, adefovir, which decreases the
incidence of lamivudine-resistant mutations, has been
administered to patients demonstrating a ﬂare-up of
hepatitis. The aims of this study were to clarify (1) the
long-term efﬁcacy of the lamivudine treatment of Japanese
patients with chronic hepatitis B with or without adefovir
add-on treatment of breakthrough hepatitis due to lamivu-
dine resistance, (2) the rate of both occurrence of the
lamivudine-resistant mutant virus and recurrence of hepa-
titis related to the lamivudine-resistant virus, and (3) the
long-term consequences of the lamivudine and adefovir
combination therapy for chronic hepatitis B.
Patients and methods
Eligible patients were enrolled at Fukuoka University
Hospital. The key inclusion criteria were seropositivity for
hepatitis B surface antigen and serum HBV DNA. Both
HBeAg-positive and HBeAg-negative patients were
included. Lamivudine was administered orally at a dose of
100 mg daily for the treatment of the patients who had
elevated ALT levels, namely, more than 1.5 times the
upper limit of normal. Exclusion criteria included decom-
pensated liver disease, a coexisting serious medical or
psychiatric illness, a history of alcohol or drug abuse within
1 year before entry, and coinfection with hepatitis C virus
or human immunodeﬁciency virus, and advanced hepato-
cellular carcinoma. We examined the effects of the
lamivudine treatment on the normalization of the ALT
levels, the loss of HBeAg, HBeAg seroconversion, and the
loss of serum HBV DNA at 1, 2, 3, 4, and 5 years,
respectively. To determine the factors that inﬂuenced the
occurrence of lamivudine-resistant mutation in HBV, we
also examined the pre-treatment clinical factors.
Among the patients who developed a lamivudine-resis-
tant virus, the patients who showed an elevated ALT levels
of more than two times the upper limit of normal and that
continued for longer than 2 months received adefovir at an
oral dose of 10 mg daily in addition to lamivudine. In those
patients who had adefovir in addition to lamivudine for the
treatment of recurrence hepatitis, we examined the effect of
the adefovir treatment on the normalization of the ALT
levels and the loss of serum HBV DNA since the time the
adefovir treatment was started. Furthermore, we studied the
efﬁcacy of this combination therapy on the normalization
of the ALT levels and the loss of serum HBV DNA at 1, 2,
3, 4, and 5 years, respectively, since the time the lamivu-
dine treatment was started.
The histologic improvement was analyzed in 15 patients
who underwent a second liver biopsy. The patients were
subjected to a liver biopsy using a Menghini needle guided
by ultrasonography. Formalin-ﬁxed liver specimens were
stained with hematoxylin and eosin for morphologic eval-
uations, with Masson’s trichrome staining for the
assessment of ﬁbrosis.
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123HBeAg and HBeAb were detected via a chemilumi-
nescent enzyme immunoassay (ARCHITECT HBeAg and
ARCHITECT HBeAb, Abbott Japan, Tokyo, Japan). The
serum HBV DNA levels in all patients before and during
lamivudine treatment were measured via Transcription
Mediated Ampliﬁcation (DNA probe [FR]-HBV; Fujirebio
Inc, Tokyo, Japan). The HBV levels were expressed as the
log genome equivalent per milliliter (LGE/ml) and the
upper and lower detection limits of the assay were 8.7 and
3.7 log copies/ml, respectively. The incidence of lamivu-
dine mutations in the tyrosine-methionine-aspartate-
aspartate (YMDD) motif was measured by means of a
polymerase chain reaction-enzyme linked mini-sequence
assay (PCR-ELMA; SMITEST HBV-YMDD Mutation
Detection Kit, Medical and Biological Laboratories, Nag-
ano, Japan).
Statistical analysis
Fisher’s exact test was used for sex and HBeAg positivity
for comparisons between groups. Comparisons of the
means ± standard deviations were performed using Stu-
dent’s t-test for age, the ALT level, and the serum HBV
DNA level. A P-value of less than 0.05 was considered to
be statistically signiﬁcant. For multivariate analyses, the
Cox proportional hazards model analysis was used. Ninety-
ﬁve CIs were used throughout.
Results
Patients (n = 327) who were seropositive for hepatitis B
surface antigen were from our hospital and all were Japa-
nese patients. Among these cases, 141 patients received
lamivudine as the therapy for chronic hepatitis B and 110
eligible patients have been followed for more than 1 year
(67 patients who were HBeAg-positive and 43 patients who
were HBeAg-negative) (Table 1). This study reviewed the
cumulative outcome of the patients with chronic hepatitis B
who were treated with lamivudine, and the patients who
had been followed for more than 2, 3, 4, and 5 years
numbered 94, 79, 63, and 44, respectively. The median
follow-up after the start of lamivudine was 48
(range = 12–86) months. In all patients, including those
who were either HBeAg-positive or HBeAg-negative, the
normalization of ALT levels decreased with the duration of
lamivudine treatment from 70.0% at 1 year to 56.4%,
48.3%, 49.2%, and 36.4% at 2, 3, 4, and 5 years and the
loss of serum HBV DNA decreased from 72.7% at 1 year
to 53.2%, 41.8%, 39.7%, and 31.8% at 2, 3, 4, and 5 years,
respectively (Table 2). These results included all the
patients with or without lamivudine resistance. In our
intention-to-treat analysis, the patients who had an efﬁcacy
of adefovir salvage treatment of breakthrough hepatitis
were excluded from the efﬁcacy group of lamivudine
treatment. In the HBeAg-positive patients, the normaliza-
tion of the ALT levels decreased during the lamivudine
treatment from 71.6% at 1 year to 55.7%, 42.6%, 41.9%,
and 22.6% at 2, 3, 4, and 5 years, respectively (Table 2).
Their loss of serum HBV DNA was 22.6% and HBeAg
seroconversion was 22.6% during the 5-year period of
lamivudine treatment. In the HBeAg-negative patients, the
normalization of the ALT levels was 67.4% at 1 year and
57.6%, 60.0%, 65.0%, and 69.2% at 2, 3, 4, and 5 years
and the loss of serum HBV DNA was 76.7% at 1 year and
69.7%, 66.0%, 53.0%, and 53.8% at 2, 3, 4, and 5 years,
respectively.
The occurrence of a lamivudine-resistant mutation was
seen in 60 patients. The mutation proportion increased
from 27.3% at 1 year to 43.6%, 50.1%, 53.6%, and 54.6%
Table 1 Patients baseline
demographics and disease
characteristics (n = 110)
HBeAg: Hepatitis B e antigen
a The upper limit of the normal
range is 30 IU per liter
HBeAg-positive
n = 67
HBeAg-negative
n = 43
All patients
n = 110
Gender, male:female (%male) 43:24 (64.2%) 29:14 (67.4%) 72:38 (65.6%)
Age (years)
Mean ± SD 41.0 ± 12.5 47.9 ± 9.4 43.7 ± 11.9
Median 42 47 45
Range 18–68 27–69 18–69
Alanine aminotransferase (IU/l)
a
Mean ± SD 208.5 ± 246.9 185.4 ± 238 199.3 ± 244.8
Median 110 89 92
Range 45–1148 45–907 45–1148
HBV DNA (LGE/ml)
Mean ± SD 7.52 ± 1.06 6.16 ± 1.95 6.99 ± 1.62
Median 7.6 6.9 7.3
Range 4.3–8.7 3.7–8.4 3.7–8.7
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123at 2, 3, 4, and 5 years of treatment, respectively. Table 3
shows the number of patients who developed virus recru-
descence at each year. This occurrence was more frequent
in those who were HBeAg-positive (P\0.01), those with
a low ALT level (P\0.05), and those with a high level of
serum HBV DNA (P\0.01) at the time the lamivudine
treatment was started (Table 4). Thirty-six (60.0%) of the
60 patients received adefovir for the treatment of break-
through hepatitis due to a lamivudine-resistant mutation,
whereas the other 24 patients with a slight elevation in the
ALT level did not receive adefovir. The patients who
received adefovir had signiﬁcantly higher levels of serum
HBV DNA at the time the lamivudine treatment was
started than those who did not receive adefovir (Table 5).
Cox proportional hazards model analysis was used to
determine the factors predicting viral recrudescence and
breakthrough hepatitis. The patients who had more than
7.0 LGE/ml of serum HBV DNA level at the time the
lamivudine treatment was started showed a signiﬁcantly
frequent occurrence of a lamivudine-resistant mutation
(risk ratio = 0.466, 95% CI: 0.246–0.842, P = 0.011;
Table 6). The patients who had more than 7.7 LGE/ml of
serum HBV DNA at the time the lamivudine treatment was
started more frequently received adefovir add-on therapy
for breakthrough hepatitis (risk ratio = 0.444, 95% CI:
0.218–0.879, P = 0.019; Table 6).
Table 2 The efﬁcacy of lamivudine treatment in the patients with or without lamivudine-resistance (n = 110)
At 1 year (n = 110) At 2 years (n = 94) At 3 years (n = 79) At 4 years (n = 63) At 5 years (n = 44)
All patients (n = 110)
ALT normalization 77 (70.0%) 53 (56.4%) 38 (48.3%) 31 (49.2%) 16 (36.4%)
Loss of HBV DNA 80 (72.7%) 50 (53.2%) 33 (41.8%) 25 (39.7%) 14 (31.8%)
At 1 year (n = 67) At 2 years (n = 61) At 3 years (n = 54) At 4 years (n = 43) At 5 years (n = 31)
HBeAg-positive patients (n = 67)
ALT normalization 48 (71.6%) 34 (55.7%) 23 (42.6%) 18 (41.9%) 7 (22.6%)
Loss of HBV DNA 47 (70.1%) 27 (44.3%) 19 (35.2%) 14 (32.6%) 7 (22.6%)
Loss of HBeAg 20 (29.9%) 20 (32.8%) 19 (35.2%) 13 (30.2%) 7 (22.6%)
HBeAg seroconversion 16 (23.9%) 9 (31.1%) 18 (33.3%) 13 (30.2%) 7 (22.6%)
At 1 year (n = 43) At 2 years (n = 33) At 3 years (n = 25) At 4 years (n = 20) At 5 years (n = 13)
HBeAg-negative patients (n = 43)
ALT normalization 29 (67.4%) 19 (57.6%) 15 (60.0%) 13 (65.0%) 9 (69.2%)
Loss of HBV DNA 33 (76.7%) 23 (69.7%) 14 (66.0%) 11 (53.0%) 7 (53.8%)
ALT: Alanine aminotransferase
HBeAg: Hepatitis B e antigen
Table 3 The occurrence of lamivudine-resistant mutation during
5 years
Number of
patients
Baseline HBV DNA levels
Mean ± SD (LGE/ml)
At 1 year 30 7.46 ± 1.15
At 2 years 18 7.56 ± 1.07
At 3 years 8 6.98 ± 2.35
At 4 years 3 7.46 ± 0.70
At 5 years 1 6.3
Table 4 Comparison between
those patients who had virus
recrudescence and those who
did not
HBeAg: Hepatitis B e antigen
NS: Not signiﬁcant
Virus recrudescence
(n = 60)
Non-virus recrudescence
(n = 50)
P
Age (years) mean ± SD 43.5 ± 11.4 44.4 ± 12.3 NS
Gender: male:female (%male) 44:16 (73.3%) 28:22 (56.0%) NS
HBeAg-positive patients 44 (73.3%) 23 (46.0%) \0.01
Alanine aminotransferase (IU/l)
Mean ± SD 157.9 ± 218.5 246.6 ± 261.6 \0.05
Serum HBV DNA (LGE/ml)
Mean ± SD 7.40 ± 1.36 6.49 ± 1.75 \0.01
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malization of ALT levels was 47.2%, 57.9%, and 81.8% at
1, 2, and at 3 years and their loss of serum HBV DNA was
47.2%, 68.4%, and 90.9% at 1, 2, and at 3 years, respec-
tively (Table 7). At the time of this analysis, the median
total duration of adefovir treatment was 24 (range = 12–
56) months and no adefovir-resistant mutation has been
detected in any of these patients.
Fifty patients who did not develop lamivudine resis-
tance showed the normalization of their ALT levels to be
84.0% at 1 year and 86.1%, 92.0%, 90.9%, and 91.9% at
2, 3, 4, and 5 years and the loss of serum HBV DNA was
Table 5 Comparison between
those patients who received
adefovir and those who did not
HBeAg: Hepatitis B e antigen
NS: Not signiﬁcant
YMDD mutation: YMDD motif
of the HBV DNA polymerase
YIDD: Methionine to isoleucine
YVDD: Methioneine to valine
Administration of
adefovir (n = 36)
No administration of
adefovir (n = 24)
P
Age (years) mean ± SD 45.0 ± 10.5 41.3 ± 12.3 NS
Gender: male:female (%male) 29:7 (80.1%) 15:9 (62.5%) NS
HBeAg-positive patients 25 (69.4%) 19 (79.2%) NS
Alanine aminotransferase (IU/l)
Mean ± SD 148.7 ± 202.5 170.0 ± 239.6 NS
Serum HBV DNA (LGE/ml)
Mean ± SD 7.64 ± 1.03 6.91 ± 1.30 \0.05
YMDD mutation YIDD 20 YIDD 13
YVDD 8 YVDD 4
YIDD + YVDD 3 YIDD + YVDD 0
Table 6 Multivariate analysis with Cox proportional hazards model
Variable P-value Risk ratio 95% CI
Virus recrudescence HBV DNA37.0 LGE/ml 0.011 0.466 0.246–0.842
Breakthrough HBV DNA37.7 LGE/ml 0.019 0.444 0.218–0.879
Only variables that achieved statistical signiﬁcance (P\0.05) are shown
CI: Conﬁdence interval
Breakthrough; administration of adefovir for breakthrough hepatitis due to lamivudine resistance
Table 7 The efﬁcacy of the adefovir add-on treatment
At 1 year (n = 36) At 2 years (n = 19) At 3 years (n = 11)
All patients (n = 36)
ALT Normalization 17 (47.2%) 11 (57.9%) 9 (81.8%)
Loss of HBV DNA 17 (47.2%) 13 (68.4%) 10 (90.9%)
At 1 year (n = 25) At 2 year (n = 13) At 3 years (n = 8)
HBeAg-positive patients (n = 25)
ALT Normalization 12 (48.0%) 7 (53.8%) 7 (87.5%)
Loss of HBV DNA 9 (36.0%) 8 (61.5%) 7 (87.5%)
Loss of HBeAg 3 (12.0%) 5 (38.5%) 6 (75.0%)
HBeAg seroconversion 3 (12.0%) 5 (38.5%) 6 (75.0%)
At 1 year (n = 11) At 2 year (n = 6) At 3 years (n = 3)
HBeAg-negative patients (n = 11)
ALT Normalization 5 (45.5%) 4 (66.7%) 2 (66.7%)
Loss of HBV DNA 8 (72.7%) 5 (83.3%) 3 (100%)
ALT: Alanine aminotransferase
HBeAg: Hepatitis B e antigen
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12392.0% at 1 year and 94.4%, 96.0%, 95.5%, and 100% at
2, 3, 4, and 5 years, respectively. The results were good
for the patients who did not develop lamivudine
resistance.
Fifteen patients who were treated with lamivudine
underwent a repeat liver biopsy. The changes in stages of
liver ﬁbrosis are shown in Fig. 1. Figure 1a shows the
group of the patients whose ALT levels were more than
two times the upper limit of normal. Figure 1b shows the
group of the patients whose ALT levels were less than two
times the upper limit of normal. A progression in the
ﬁbrosis stage was observed in two patients and an
improvement in the ﬁbrosis stage was observed in 8
patients. Even if the serum HBV DNA level showed
positive values, the degree of liver ﬁbrosis improved on the
basis of the ﬁndings of a second liver biopsy in the patients
who were treated with lamivudine if the ALT level was less
than two times the upper limit of normal.
To clarify the long-term efﬁcacy of the lamivudine
treatment of Japanese patients with chronic hepatitis B with
or without adefovir add-on treatment of breakthrough
hepatitis due to lamivudine-resistance, we investigated the
efﬁcacy of the lamivudine treatment by our new approach.
Table 2 shows those patients who had an efﬁcacy of ade-
fovir salvage treatment of breakthrough hepatitis and were
excluded from the efﬁcacy group of the patients with lam-
ivudine treatment. In addition, in Table 8, the patients who
had the efﬁcacy of adefovir add-on treatment were included
in the efﬁcacy group for 5-year period since lamivudine
treatment was started. These results included all the patients
Fig. 1 A follow-up study of liver histology on the patients with
chronic hepatitis B treated with lamivudine. (a) Four patients whose
alanine aminotransferase levels were more than 2 times the upper
limit of normal showed no improvement in liver ﬁbrosis at the second
liver biopsy. (b) Nine patients whose alanine aminotransferase levels
were less than 2 times the upper limit of normal demonstrated an
improvement in liver ﬁbrosis at the second liver biopsy even if the
serum HBV DNA was positive. Another 3 patients whose degree of
ﬁbrosis was diagnosed to be F1 at the ﬁrst liver biopsy showed no
change in liver ﬁbrosis
Table 8 The efﬁcacy of lamivudine treatment with or without adefovir add-on (n = 110)
At 1 year (n = 110) At 2 years (n = 94) At 3 years (n = 79) At 4 years (n = 63) At 5 years (n = 44)
All patients (n = 110)
ALT normalization 77 (70.0%) 55 (58.5%) 48 (60.8%) 42 (66.7%) 27 (61.4%)
Loss of HBV DNA 80 (72.7%) 55 (58.5%) 43 (54.4%) 36 (57.1%) 27 (61.4%)
At 1 year (n = 67) At 2 years (n = 61) At 3 years (n = 54) At 4 years (n = 43) At 5 years (n = 31)
HBeAg-positive patients (n = 67)
ALT normalization 48 (71.6%) 34 (55.7%) 29 (53.7%) 26 (60.5%) 17 (54.8%)
Loss of HBV DNA 47 (70.1%) 27 (44.3%) 24 (44.4%) 21 (48.8%) 16 (51.6%)
Loss of HBeAg 20 (29.9%) 20 (32.8%) 20 (37.0%) 18 (41.9%) 14 (45.2%)
HBeAg seroconversion 16 (23.9%) 19 (31.1%) 19 (35.2%) 18 (41.9%) 14 (45.2%)
At 1 year (n = 43) At 2 years (n = 33) At 3 years (n = 25) At 4 years (n = 20) At 5 years (n = 13)
HBeAg-negative patients (n = 43)
ALT Normalization 29 (67.4%) 21 (63.6%) 19 (76.0%) 16 (80.0%) 10 (76.9%)
Loss of HBV DNA 33 (76.7%) 28 (84.8%) 19 (76.0%) 15 (75.0%) 11 (84.6%)
ALT: Alanine aminotransferase
HBeAg: Hepatitis B e antigen
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123with or without lamivudine-resistance and all the patients
with or without adefovir add-on therapy. In all these
patients, including those who were HBeAg-positive and
those who were HBeAg-negative, the normalization of the
ALT levels was 61.4% at 5 years since lamivudine treat-
ment was started (Table 8). The loss of serum HBV DNA
was 61.4% at 5 years since the lamivudine treatment was
started. In the HBeAg-positive patients, the normalization
of the ALT levels, the loss of serum HBV DNA, and
HBeAg seroconversion was 54.8%, 51.6%, and 45.2% at
5 years, respectively, since the lamivudine treatment was
started. In the HBeAg-negative patients, the normalization
of the ALT levels and the loss of serum HBV DNA was
76.9% and 84.6% at 5 years, respectively, since the lami-
vudine treatment had been started.
Discussion
We herein describe the long-term efﬁcacy of lamivudine
treatment over a 5-year period. In all patients, including
those who were HBeAg-positive and those who were
HBeAg-negative, the normalization of ALT levels and the
loss of serum HBV DNA gradually decreased to 36.4% and
31.8% at 5 years, respectively. The efﬁcacy of lamivudine
treatment was only about 30%. This result showed that
lamivudine monotherapy could not improve the long-term
outcomes in the patients with chronic hepatitis B. How-
ever, in the HBeAg-negative patients, the effects of
lamivudine treatment were maintained for long-term.
Although we assessed only a small number of patients in
this study, we consider lamivudine monotherapy to be an
effective treatment modality for patients with HBeAg-
negative chronic hepatitis B to improve the long-term
outcomes. On the other hand, because in the HBeAg-
positive patients, virus recrudescence was more frequently
observed than in the HBeAg-negative patients, the efﬁcacy
of the lamivudine treatment for 5 years was only about
20%. HBeAg-positive patients who demonstrated a high
value of serum HBV DNA level and a low ALT level at the
start of the lamivudine therapy showed a signiﬁcant cor-
relation with an increase in the occurrence of lamivudine-
resistant mutations. Our Cox proportional hazards model
analysis shows that to obtain serum HBV DNA levels of
less than 7.7 LGE/ml before lamivudine treatment might
associate with good outcomes in those patients. These
patients are therefore recommended to reduce their serum
HBV DNA levels before commencing lamivudine treat-
ment and using interferon a or other therapeutic options [5,
6, 12]. Further large-scale and long-term studies are needed
to conﬁrm these observations.
In our study, although most virus recrudescence was
observed within 1 year after the lamivudine treatment, 1
patient demonstrated virus recrudescence at 5 years after
the lamivudine treatment was started. This is a very
important ﬁnding and we must therefore carefully monitor
the serum HBV DNA levels of the patients even if they
show a good long-term response to the lamivudine treat-
ment. Thirty-six of the patients with virus-recrudescence
had adefovir added to the lamivudine regimen for the
treatment of breakthrough hepatitis. However, the other 24
patients (40%) did not need adefovir to be added to the
treatment regimen because they did not demonstrate
hepatitis. In our study, even if the serum HBV DNA level
was found to be positive, a histologic improvement was
obtained in patients with ALT levels that were under 2
times the upper limit of normal at the time of a second liver
biopsy. We thus consider that the normalization of ALT
levels might therefore be more important than achieving a
negative serum HBV DNA state to achieve a remission of
liver disease. However, the risks of hepatocellular carci-
noma and cirrhosis in the patients with chronic hepatitis B
have recently been reported to be related to the serum HBV
DNA levels [13, 14]. Our 24 patients who did not have
adefovir added to the treatment regimen, even if they had
virus recrudescence, all required a long-term follow-up to
monitor whether or not they might progress to either
cirrhosis or hepatocellular carcinoma.
Some reports have shown that among patients who
experienced HBeAg seroconversion during the lamivudine
treatment, the durability of the response after the cessation
of therapy ranged from 38% to 77% [15–17]. Because
lamivudine therapy still continues to be administered in
Japan to avoid any posttreatment ﬂare-ups of hepatitis
[18–20], our patients continue to receive lamivudine
treatment; therefore, our data are not comparable with
other studies involving a cessation of treatment.
Previous studies reported that in patients receiving
adefovir, the HBV DNA level decreased by 3.5 to 3.9 log10
from the baseline level [21, 22]. In addition, studies from
Asia reported that patients with lamivudine resistance have
been treated with adefovir either in monotherapy or in
combination with lamivudine without any signiﬁcant dif-
ferences between the 2 regimens [23, 24]. On the other
hand, studies from Europe reported that adding adefovir to
lamivudine for the treatment of patients with lamivudine-
resistant HBeAg-negative chronic hepatitis B maximizes
the anti-viral efﬁcacy because of the absence of viral
resistance [25, 26]. In Japan, adefovir has been used as an
additional therapy to suppress viral replication with lami-
vudine-resistant mutations. In all the patients investigated
in our study, adefovir was added to the lamivudine regi-
men. However, no virologic or biochemical breakthrough
was reported because no adefovir-resistance occurred in
any of our patients. We thus considered that the condition
of no adefovir-resistance might have occurred as all
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123our patients received adefovir in combination with
lamivudine.
To clarify the long-term efﬁcacy of the lamivudine
treatment of Japanese patients with chronic hepatitis B, we
investigated the efﬁcacy of lamivudine treatment on the
basis of our new approach. In all the patients with or
without lamivudine resistance and with or without adefovir
add-on treatment, the normalization of the ALT levels was
61.4% and the loss of serum HBV DNA was 61.4% after
the 5-year period of treatment from the time of lamivudine-
treatment. This study is the ﬁrst report to clarify the long-
term efﬁcacy of lamivudine treatment either with or
without adefovir from the time the lamivudine treatment
was started. Our study suggests that even in patients with
chronic hepatitis B who have a high HBV DNA level and/
or who are HBeAg-positive, the combination therapy of
lamivudine and adefovir appears to be an effective treat-
ment modality. This is a retrospective observational study
with a relatively heterogeneous patient population.
Although this study has its limitation, it represents the real
situation for the treatment of chronic hepatitis B in Japan.
The advantages of this study, such as being a single-center
study, where all tests were performed in the same labora-
tory using the same methods, are thus considered to
outweigh these limitations. These preliminary observations
need to be validated in future studies with a larger number
of patients.
In conclusion, although the efﬁcacy of lamivudine is
limited because of breakthrough hepatitis, adefovir was
used as a salvage treatment of lamivudine resistance in
patients with chronic hepatitis B. Therefore, the use of
lamivudine for the treatment of Japanese patients with
chronic hepatitis B with or without lamivudine-resistance
is thus considered to be a useful treatment modality for
obtaining long-term virologic and biochemical responses.
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